Clinical Monograph: Nitrazepam 5 mg

1. Classification and Chemical Overview

Nitrazepam is a chlorinated nitrobenzodiazepine derivative chemically designated as 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one. Under the Anatomical Therapeutic Chemical (ATC) system, nitrazepam is indexed under N05CD02.

The 5 mg strength represents a standard adult therapeutic dose for insomnia management. Internationally, nitrazepam is classified as a Controlled Substance (Schedule IV under the US Controlled Substances Act; Schedule 3 / Class C Controlled Drug in the UK) due to its risks of tolerance, physical dependence, and misuse. It is regulated strictly as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Nitrazepam produces hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties via allosteric modulation of central nervous system receptors:

• FRONTA​ Receptor Potentiation: Binds with high affinity to the benzodiazepine binding site located on the FRONTA​ receptor complex.

• Chloride Conductance Enhancement: Facilitates GABA-mediated opening of chloride ion channels, hyperpolarizing the neuronal membrane and suppressing electrical excitability across sleep-promoting centers in the brainstem and limbic system.

• Sleep Architecture Alteration: Decreases sleep latency, reduces nocturnal awakenings, and prolongs total sleep duration, though prolonged use can alter normal sleep architecture (e.g., reducing REM sleep).

3. Approved Clinical Indications and Dosing Scope

Licensing for nitrazepam includes:

• Severe Insomnia: Short-term management of severe, disabling insomnia that is causing profound distress or exhaustion in adults.

Dosing & Administration Regimen:

• Adult Dosage: Typically 5 mg to 10 mg taken orally immediately before bedtime. In elderly or debilitated patients, initial dosing should not exceed 5 mg due to heightened sensitivity and risks of excessive sedation or ataxia.

• Duration Restrictions: Treatment duration should be kept to the absolute minimum (typically not exceeding 2 weeks) to minimize the risk of dependence and tolerance.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Readily absorbed from the gastrointestinal tract, with peak plasma concentrations (Cmax​) attained within 2 hours (Tmax​).

• Distribution: Highly lipophilic with extensive tissue distribution; plasma protein binding is approximately 85% to 88%. Crosses the blood-brain barrier, placenta, and enters human breast milk.

• Biotransformation: Extensively metabolized in the liver primarily via nitroreduction by Cytochrome P450 enzymes and subsequent acetylation to inactive amino metabolites (7-aminonitrazepam and 7-acetamidonitrazepam).

• Elimination: Excreted predominantly in urine as conjugated metabolites. Nitrazepam is a medium-to-long-acting agent with an elimination half-life (t1/2​) ranging from 15 to 38 hours, which can lead to next-day residual sedation (“hangover effect”).

5. Physiological Effects and Adverse Event Spectrum

Nitrazepam depresses central nervous system function, dampens psychomotor performance, and relaxes skeletal muscle tone.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Residual daytime drowsiness, daytime sedation, lightheadedness, impaired coordination, ataxia.

• Common ($\ge 1/100$ to $<1/10$): Confusion, dizziness, headache, muscle weakness, visual disturbances, emotional lability, fatigue.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Paradoxical reactions (agitation, aggression, rage, irritability), anterograde amnesia, skin rash, gastrointestinal distress, changes in libido.

• Rare / Severe (<1/1,000): Severe respiratory depression, blood dyscrasias (leukopenia, thrombocytopenia), severe withdrawal syndrome, hepatic dysfunction.

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Known hypersensitivity to nitrazepam or other benzodiazepines.

• Severe acute respiratory insufficiency or respiratory depression.

• Sleep apnea syndrome.

• Myasthenia gravis.

• Severe hepatic impairment.

• Acute narrow-angle glaucoma.

Key Drug Interactions

• CNS Depressants, Opioids, & Alcohol: Co-administration results in profound, synergistic central nervous system and respiratory depression, significantly elevating the risk of fatal overdose, coma, and respiratory arrest.

• CYP3A4 Inhibitors & Inducers: Inhibitors (e.g., erythromycin, ketoconazole) can reduce clearance and enhance sedation, while inducers (e.g., rifampicin, carbamazepine) accelerate metabolism and reduce efficacy.

Clinical Precautions and Monitoring

• Boxed Warning (Concomitant Opioid Use & Abuse/Dependence): Combined use with opioids increases the risk of severe respiratory depression and death. Long-term continuous use leads to physical and psychological dependence.

• Rebound Insomnia & Withdrawal: Abrupt cessation after regular use triggers an acute withdrawal syndrome characterized by severe rebound insomnia, anxiety, tremors, sweating, and, in severe cases, convulsions. Tapering is mandatory.

• Falls Risk in Elderly: Due to its long half-life and residual sedative effects, nitrazepam significantly increases the risk of daytime falls, confusion, and hip fractures in elderly populations; use with extreme caution.